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1. INTRODUCTION {#pbc26272-sec-0060}
===============

Undifferentiated embryonal sarcoma of the liver (UESL) is a rare neoplasm that accounts for 9--15% of pediatric liver malignancies[1](#pbc26272-bib-0001){ref-type="ref"} and is the third most common malignant liver tumor in children, following hepatoblastoma and hepatocellular carcinoma.[2](#pbc26272-bib-0002){ref-type="ref"} The peak incidence of UESL is between 6 and 10 years of age.[1](#pbc26272-bib-0001){ref-type="ref"}, [3](#pbc26272-bib-0003){ref-type="ref"} Some series report a female predominance,[4](#pbc26272-bib-0004){ref-type="ref"} while others report an even‐gender distribution.[1](#pbc26272-bib-0001){ref-type="ref"}, [5](#pbc26272-bib-0005){ref-type="ref"}, [6](#pbc26272-bib-0006){ref-type="ref"} Tumor sizes are between 10 and 30 cm.[7](#pbc26272-bib-0007){ref-type="ref"} UESL arises more commonly from the right lobe of the liver and presents clinically with nonspecific symptoms of abdominal pain, fever, nausea, and anorexia.[1](#pbc26272-bib-0001){ref-type="ref"}, [3](#pbc26272-bib-0003){ref-type="ref"}, [4](#pbc26272-bib-0004){ref-type="ref"}, [5](#pbc26272-bib-0005){ref-type="ref"}, [7](#pbc26272-bib-0007){ref-type="ref"} Imaging demonstrates cystic and solid components,[8](#pbc26272-bib-0008){ref-type="ref"}, [9](#pbc26272-bib-0009){ref-type="ref"}, [10](#pbc26272-bib-0010){ref-type="ref"} and serum α‐fetoprotein is usually normal. Historically, treatment was limited to radical surgical resection, with chemotherapy and radiation used infrequently, leading to a dismal prognosis with a median overall survival (OS) of less than 1 year.[1](#pbc26272-bib-0001){ref-type="ref"} Mortality was primarily from recurrent and metastatic disease.[1](#pbc26272-bib-0001){ref-type="ref"}, [11](#pbc26272-bib-0011){ref-type="ref"}, [12](#pbc26272-bib-0012){ref-type="ref"} More recently, aggressive treatment regimens that combine chemotherapy and surgical resection have improved survival substantially.[5](#pbc26272-bib-0005){ref-type="ref"}, [13](#pbc26272-bib-0013){ref-type="ref"}, [14](#pbc26272-bib-0014){ref-type="ref"}

Due to its low incidence, much of the literature regarding UESL is from small case series or case reports. The largest series from 1978 had 31 patients, and no adult series has more than two cases.[5](#pbc26272-bib-0005){ref-type="ref"}, [15](#pbc26272-bib-0015){ref-type="ref"} Therefore, few data exist to help guide therapy and counsel patients and their families. Previously reported factors associated with worse OS are local recurrence, tumor rupture, and metastatic disease.[4](#pbc26272-bib-0004){ref-type="ref"}, [16](#pbc26272-bib-0016){ref-type="ref"} Outside of meta‐analyses, there are no large retrospective single‐source analyses of UESL characteristics and prognostic factors. The National Cancer Database (NCDB) is a U.S.‐based, nationwide multi‐institutional database that is jointly managed by the American College of Surgeon\'s Commission on Cancer (CoC) and the American Cancer Society. It captures approximately 70% of all newly diagnosed cases of cancer in the United States from over 1,500 participating CoC programs.[17](#pbc26272-bib-0017){ref-type="ref"} Because of its large scale, the NCDB provides a unique opportunity to examine rare pathologies such as this one, where the previous literature is limited. This study aims to outline the patient and disease characteristics, as well as identify factors that correlate with OS in children with UESL using the largest dataset to date from the NCDB.

2. METHODS {#pbc26272-sec-0070}
==========

2.1. Data source and study population {#pbc26272-sec-0080}
-------------------------------------

This dataset was obtained from the NCDB Participant User File (PUF) for liver neoplasms. The PUF files are deidentified for patient and facility‐specific information in accordance with the requirements of the Health Insurance Portability and Accountability Act. This study was limited to patients \<18 years with primary UESL, who were diagnosed between 1998 and 2012. The dataset was queried using tumor histology codes from the International Classification of Disease for Oncology 3rd Edition (ICD‐O‐3): code 8805 for undifferentiated sarcoma and code 8991 for embryonal sarcoma.

2.2. Variables {#pbc26272-sec-0090}
--------------

The variables that were chosen to be included in the analysis were limited to those with fewer than 20% incomplete data and can be found in Table [1](#pbc26272-tbl-0001){ref-type="table-wrap"}. Income and education levels were derived from the 2008 U.S. Census data based on the patients' reported zip code of residence. The variable "Treatment Modality" refers to whether patients had no treatment, chemotherapy only, surgical resection only, or combined therapy. Combined therapy refers to the combination of chemotherapy and surgical resection of any kind. Radiation therapy was not included in this variable, as a small minority of patients had radiation therapy as part of their treatment course.

###### 

Demographic, tumor, and treatment characteristics

                                                                                         N = 103, n (% of N)
  -------------------------------------------------------- ----------------------------- ---------------------
  Age                                                      Median                        9 (0--17)
  Gender                                                   Male                          52 (50)
                                                           Female                        51 (50)
  Race                                                     Caucasian                     85 (83)
                                                           African American              11 (11)
                                                           Other                         5 (5)
                                                           Unknown                       2 (2)
  Spanish origin                                           Non‐Hispanic                  68 (66)
                                                           Hispanic                      26 (25)
                                                           Unknown                       9 (9)
  Insurance status                                         Public                        41 (40)
                                                           Private                       55 (53)
                                                           None                          3 (3)
                                                           Unknown                       4 (4)
  Income                                                   \<\$63,000                    75 (73)
                                                           ≥\$63,000                     26 (25)
                                                           Unknown                       2 (2)
  Tumor size                                               Median (IQR)                  14 cm (11--16 cm)
                                                           \<15 cm                       57 (55)
                                                           ≥15 cm                        30 (29)
                                                           Unknown                       16 (16)
  Metastases[a](#pbc26272-tbl1-note-0002){ref-type="fn"}   Not present                   54 (81)
                                                           Present                       10 (15)
                                                           Unknown                       3 (4)
  Lymph node status                                                                      
                                                           Negative                      21 (20)
                                                           Positive                      1 (1)
                                                           Not sampled                   73 (71)
                                                           Unknown                       8 (8)
  Radiation therapy                                                                      
                                                           No                            85 (83)
                                                           Yes                           15 (15)
                                                           Unknown                       3 (3)
  Margins of resection                                                                   
                                                           Negative                      51 (57)
                                                           Positive                      20 (22)
                                                           Unknown                       19 (21)
  Treatment modality                                       Chemotherapy only             9 (9)
                                                           No treatment                  4 (4)
                                                           Surgery only                  5 (5)
                                                           Combined therapy              84 (82)
                                                           Unknown                       1 (1)
  Chemotherapy                                             No                            9 (9)
                                                           Yes                           93 (90)
                                                           Unknown                       1 (1)
  Resection type                                           No surgery                    13 (13)
                                                           Local destruction             0 (0)
                                                           Sectionectomy                 29 (28)
                                                           Hemihepatectomy               38 (37)
                                                           Trisectionectomy              10 (10)
                                                           Orthotopic liver transplant   10 (10)
                                                           Surgery, NOS                  3 (3)

NOS, not otherwise specified; IQR, interquartile range.

Data missing in 36 of 103 records.

John Wiley & Sons, Ltd.

2.3. Statistical methods {#pbc26272-sec-0100}
------------------------

Continuous variables are reported as a mean or median, with the corresponding absolute range or interquartile range (IQR), respectively. Categorical variables are reported as frequencies with the corresponding percentages.

Kaplan--Meier analyses of OS were conducted for each variable; differences were tested with the log‐rank test, and 5‐year OS was calculated from mortality tables. Univariate analysis was performed using a Cox proportional hazard model. For multivariate analysis, potential confounding covariates with a *P*‐value of \<0.20 on univariate analysis were entered into a Cox proportional hazard regression model. Since the variable "treatment modality" is inclusive of the "resection" and "chemotherapy" variables, only "treatment modality" was used in the multivariate model. The optimal cutpoint for tumor size was determined using the minimum *P*‐value approach. The statistical analysis was performed using STATA 13.0 (StataCorp LP, College Station, TX) and SAS 9.3 (SAS Institute, Inc., Cary, NC).

3. RESULTS {#pbc26272-sec-0110}
==========

3.1. Study population and demographic variables {#pbc26272-sec-0120}
-----------------------------------------------

A total of 103 children (age \<18 years) with a primary diagnosis of UESL between 1998 and 2012 were identified in the NCDB registry. Survival data were available for 100 of these children.

3.2. Demographics, tumor extent, and treatment {#pbc26272-sec-0130}
----------------------------------------------

The demographic, tumor, and treatment characteristics are summarized in Table [1](#pbc26272-tbl-0001){ref-type="table-wrap"}. Children with UESL had a median age of 9 years (IQR: 5--12 years) and no gender predilection. The median size was 14 cm (IQR: 11--16 cm). Lymph nodes were sampled in only 22 of 89 (25%) patients who underwent a surgical operation. Of these, lymph node involvement was seen in 1 of 22 (4.5%) nodes sampled. Combined therapy was utilized in a great majority of cases (82%). Eighty‐nine (86%) patients underwent resection, while 13 (13%) did not. Among the patients who had surgery, hemihepatectomy (37%) and sectionectomy (28%) were the most commonly utilized methods of resection. Almost all patients were treated with chemotherapy (90%), while only 15 (15%) had radiation therapy. All patients who had radiation also underwent combined chemotherapy and surgical resection. Metastases were present in 15% of patients. Among patients who did not have surgery, metastatic disease was present in three (38%) patients compared to seven (13%) patients who did have surgery. Ten orthotopic liver transplants (OLT) were also performed, and all these patients survived to 5 years. A margin‐free resection was achieved in 51 of 89 (57%) children who underwent resection, and all children with positive margins received chemotherapy.

3.3. Survival analysis {#pbc26272-sec-0140}
----------------------

### 3.3.1. Univariate analysis {#pbc26272-sec-0150}

Table [2](#pbc26272-tbl-0002){ref-type="table-wrap"} shows the results of the univariate survival analysis. The 5‐year OS for the entire patient population was 86%. In children who underwent combined therapy, the 5‐year OS was 92%. Factors associated with better OS were combined therapy (*P* \< 0.01), sectionectomy (*P* = 0.03), and hemihepatectomy (*P* = 0.001). Unknown tumor size is likely only significant as it comprises a larger proportion of patients who did not have surgery. Socioeconomic factors such as gender, race, ethnicity, insurance type, and income did not have an impact on survival. Chemotherapy alone, radiation, and surgical margins were not significant prognostic factors. All the patients who had radiation treatment also had combined therapy. There was no significant difference in survival within the combined therapy group with the addition of radiation treatment (*P* = 0.26). Radiation was also not used exclusively for patients with positive margins. Radiation was given to six patients with negative margins and seven patients with positive margins, two patients had margins that were unknown. The OS of the five patients who had surgical resection alone was 100%. There was one sectionectomy, two hemihepatectomies, one trisectionectomy, and one OLT. All these patients had negative margins.

###### 

Univariate survival analysis and 5‐year overall survival (OS) of demographic, tumor, and treatment characteristics

                                                      N = 100                                 
  -------------------- ----------------------------- ---------- ---------------- ------------ --------
  Gender               Male                             REF                                      80
                       Female                           0.43       0.13--1.4         0.16        92
  Race                 Caucasian                        REF                                      87
                       African American                 0.60       0.08--4.7         0.63        89
                       Other                            1.83        0.24--14         0.56        67
                       Unknown                           ‐             ‐              ‐          ‐
  Spanish origin       Non‐Hispanic                     REF                                      82
                       Hispanic                         0.47       0.10--2.1         0.32        92
                       Unknown                           ‐             ‐              ‐          ‐
  Insurance status     Public                           REF                                      87
                       Private                          0.83       0.25--2.7         0.76        88
                       None                             7.5         0.87--66         0.07        50
                       Unknown                          0.28       0.12--4.6         0.37        75
  Income               \<\$63,000                       REF                                      82
                       ≥\$63,000                        0.22       0.03--1.7         0.15        96
                       Unknown                           ‐             ‐              ‐          ‐
  Tumor size           \<15 cm                          REF                                      92
                       ≥15 cm                           1.9        0.49--7.8         0.35        85
                       **Unknown**                    **5.1**     **1.4--19**      **0.02**    **69**
  Radiation therapy    No                               REF                                      86
                       Yes                              1.1        0.24--4.9         0.91        84
                       Unknown                           ‐             ‐              ‐          ‐
  Margins              Negative                         REF                                      95
                       Positive                         4.4         0.73--26         0.11        83
                       Unknown                          1.3         0.11--14         0.85     
  Treatment modality   Chemotherapy only                REF                                      44
                       No treatment                     1.27       0.25--6.6        0.775        50
                       Surgery only                      ‐             ‐              ‐          ‐
                       **Combined therapy**           **0.10**   **0.03--0.33**   **\<0.01**   **92**
                       Unknown                           ‐             ‐              ‐          ‐
  Chemotherapy         No                                                                     
                       REF                                                            78      
                       Yes                              0.44       0.10--2.0         0.29        87
                       Unknown                           ‐             ‐              ‐          ‐
  Resection type       No surgery                       REF                                      46
                       Local destruction                 ‐             ‐              ‐          ‐
                       **Sectionectomy**              **0.09**   **0.02--0.45**   **0.003**    **93**
                       **Hemihepatectomy**            **0.10**   **0.03--0.39**   **0.001**    **90**
                       Trisectionectomy                 0.14       0.02--1.1         0.07        86
                       Orthotopic liver transplant       ‐             ‐              ‐          ‐
                       Surgery, NOS                      ‐             ‐              ‐          ‐

REF, reference variable; NOS, not otherwise specified; HR, hazard ratio; CI, confidence interval; '‐', insufficient cases for analysis. *P* values \<0.05 are shown in bold.

John Wiley & Sons, Ltd.

OS was 91% in patients who did not have metastatic disease (*N* = 51) and 70% in patients who did (*N* = 10). The OS for patients who had metastatic disease and underwent combined therapy was 86% (*N* = 7). It is important to note that the presence of metastatic disease was only recorded in 64 of 103 records.

The OS of the pediatric transplant patients was 100% (*N* = 10). Nine of 10 children had chemotherapy with OLT. The mean tumor size of transplant patients was 13.7 cm (1.4--24 cm).

### 3.3.2. Multivariate analysis {#pbc26272-sec-0160}

Table [3](#pbc26272-tbl-0003){ref-type="table-wrap"} shows the results of the Cox model multivariate analysis for OS. The covariates used in the model were gender, insurance, income, tumor size, tumor margins, and treatment modality. The ending sample size in this model was 100.

###### 

Multivariate Cox proportional hazards regression

                                                 N = 100                     
  ---------------------- ---------------------- ---------- ----------------- ------------
  Gender                 Male                      REF                       
                         Female                    0.49        0.13--1.9         0.30
  Insurance status       Public                    REF                       
                         Private                   1.4         0.38--5.1         0.61
                         None                      3.8         0.23--62          0.36
                         Unknown                   4.3         0.31--61          0.28
  Income                 \<\$63,000                REF                       
                         ≥\$63,000                 0.47        0.06--4.0         0.50
                         Unknown                    --            --              --
  Tumor size             \<15 cm                   REF                       
                         **≥15 cm**              **8.1**      **1.3--48**      **0.02**
                         Unknown                   4.7          1.0--22          0.05
  Treatment modality     Chemotherapy only         REF                       
                         No treatment              2.2         0.25--19          0.49
                         Surgery only               --            --              --
                         **Combined therapy**    **0.03**   **0.004--0.27**   **\<0.01**
                         Unknown                    --            --              --
  Margins of resection   Negative                  REF                       
                         Positive                  5.7         0.96--37          0.07
                         Not applicable             --            --              --
                         Unknown                   1.3         0.10--17          0.86

REF, reference variable; HR, hazard ratio; CI, confidence interval; "--", insufficient cases for analysis. *P* values \<0.05 are shown in bold.

John Wiley & Sons, Ltd.

Tumor size ≥15 cm (hazard ratio \[HR\] = 8.1, 95% CI = 1.3--48; *P* = 0.02) and combined therapy (HR = 0.03, 95% CI = 0.004 -- 0.27; *P* \< 0.01) were the only two independent prognostic factors.

4. DISCUSSION {#pbc26272-sec-0170}
=============

The purpose of this study was to broadly characterize patient and disease characteristics and identify factors associated with prognosis in UESL using the largest dataset of patients to date from the NCDB. There is currently a paucity of data related to demographics, tumor characteristics, prognostic indicators, and optimal treatment in patients with UESL. This analysis demonstrates that surgical resection alone, and combined therapy were associated with the best prognosis.

In prior decades, prognosis for UESL was considered poor; the long‐term disease‐free survival rate was less than 37%.[1](#pbc26272-bib-0001){ref-type="ref"}, [3](#pbc26272-bib-0003){ref-type="ref"}, [18](#pbc26272-bib-0018){ref-type="ref"}, [19](#pbc26272-bib-0019){ref-type="ref"} However, these data were from an era that preceded the widespread use of combined therapy as the preferred treatment. Since then, the long‐term survival rate of UESL patients has steadily improved (Table [4](#pbc26272-tbl-0004){ref-type="table-wrap"}) and is currently reported to be \>70%.[5](#pbc26272-bib-0005){ref-type="ref"}, [14](#pbc26272-bib-0014){ref-type="ref"}, [20](#pbc26272-bib-0020){ref-type="ref"}, [21](#pbc26272-bib-0021){ref-type="ref"}, [22](#pbc26272-bib-0022){ref-type="ref"}, [23](#pbc26272-bib-0023){ref-type="ref"}, [24](#pbc26272-bib-0024){ref-type="ref"}, [25](#pbc26272-bib-0025){ref-type="ref"} Some of the first cases of long‐term survivors treated with combination chemotherapy and surgery were described in the late 1980s.[26](#pbc26272-bib-0026){ref-type="ref"} Newman et al. reported long‐term survival in two of four patients.[27](#pbc26272-bib-0027){ref-type="ref"} Urban et al. then reported a series of four survivors, who were followed for 22--79 months.[28](#pbc26272-bib-0028){ref-type="ref"} The only prospective study of UESL treatment outcomes was reported by the Italian and German Soft Tissue Sarcoma Cooperative Group. From 1979 to 1996, 17 patients with UESL were identified and treated with the current regimens for pediatric rhabdomyosarcoma, and/or surgical resection, when appropriate. The authors reported following up on 13 survivors for periods ranging from 14 to 240 months. Three patients died of their disease, two had local recurrence, and one was incompletely resected.[5](#pbc26272-bib-0005){ref-type="ref"} The addition of chemotherapy to surgical management is now increasingly being employed and has been credited with increasing the OS for UESL.[5](#pbc26272-bib-0005){ref-type="ref"}, [14](#pbc26272-bib-0014){ref-type="ref"}, [28](#pbc26272-bib-0028){ref-type="ref"}, [29](#pbc26272-bib-0029){ref-type="ref"}, [30](#pbc26272-bib-0030){ref-type="ref"} This analysis supports these prior, smaller case series, which suggested that surgical resection alone, as well as combined therapy, were positive predictors of survival.

###### 

Published reports of UESL (N \> 3) from 1987 to 2014. Follow‐up and outcome of patients who had surgical resection only, as well as combined therapy, are outlined

                                                                                                                  Surgical excision Only                   Combined therapy                                                                                                                       
  ------------------------------------------------------------------ ---- ---------------- ------ ------------------------------------------------------- ------------------ ------------------------------------------------- -------------------------------------------------------- --------- ---------------------------------------------------
  Techavichit et al., 2016[20](#pbc26272-bib-0020){ref-type="ref"}    6        5--22        3/3                              0                                    --                                --                                                    5                              10--133    4/5[a](#pbc26272-tbl4-note-0002){ref-type="fn"}
  Cao et al., 2014[25](#pbc26272-bib-0025){ref-type="ref"}            9        6--37        6/3                              1                                    34                                0/1                                                   8                               5--76                           7/8
  Walther et al., 2014[21](#pbc26272-bib-0021){ref-type="ref"}        6        7--13        4/2    1 (1 OLT)[b](#pbc26272-tbl4-note-0003){ref-type="fn"}          84                                1/1                                               5 (2 OLT)                          12--48                           5/5
  Plant et al., 2013[35](#pbc26272-bib-0035){ref-type="ref"}          5        10--19       4/1                              0                                    --                                --                                                5 (1 OLT)                          21--68                           5/5
  Ismail et al., 2013[23](#pbc26272-bib-0023){ref-type="ref"}         10   4 months to 17   8/2                              0                                    --                                --                          10 (1 OLT)[c](#pbc26272-tbl4-note-0004){ref-type="fn"}   50--222                         9/10
  Upadhyaya et al., 2010[24](#pbc26272-bib-0024){ref-type="ref"}      11   4 months to 15    --                              1                                    NR                                1/1                                                   10                               --                            7/10
  Weitz et al., 2007[13](#pbc26272-bib-0013){ref-type="ref"}          5          --          --                             --                                    --                                --                                                    --                               --        [d](#pbc26272-tbl4-note-0005){ref-type="fn"}
  Bisogno et al., 2002[5](#pbc26272-bib-0005){ref-type="ref"}         17   4 months to 16   10/7                             1                                    NR          0/1[e](#pbc26272-tbl4-note-0006){ref-type="fn"}                             15                             14--240   12/15[f](#pbc26272-tbl4-note-0007){ref-type="fn"}
  Kim et al., 2002[14](#pbc26272-bib-0014){ref-type="ref"}            6        7--13        4/2                              0                                    --                                --                                                    6                              22--108                          5/6
  Webber et al., 1999[3](#pbc26272-bib-0003){ref-type="ref"}          7        2--12        4/3                              0                                    --                                --                                                    7                              6--150                           4/7
  Urban et al., 1993[28](#pbc26272-bib-0028){ref-type="ref"}          4        6--13        0/4                              0                                    --                                --                                                    4                              22--79                           4/4
  Walker et al., 1992[18](#pbc26272-bib-0018){ref-type="ref"}         4        7--29        2/2                              2                                 18--240                              2/2                                                   2                              13--30                           1/2
  Lack et al., 1991[19](#pbc26272-bib-0019){ref-type="ref"}           16       2--21        10/6                             7                                  4--12                               0/7                                                   9                               4--60                           3/9
  Leuschner et al., 1990[26](#pbc26272-bib-0026){ref-type="ref"}      9        4--20        5/4                              5                                  3--24         2/4[g](#pbc26272-tbl4-note-0008){ref-type="fn"}                             3                              15--59                           3/3
  Newman et al., 1989[27](#pbc26272-bib-0027){ref-type="ref"}         4        5--13        2/2                              0                                    --                                --                                                    4                                --                             2/4
  Horowitz et al., 1987[12](#pbc26272-bib-0012){ref-type="ref"}       5        4--16        4/1                              1                                    6                                 0/1                                                   4                              12--58                           2/4

NR, not reported; OLT, orthotopic liver transplant.

One patient underwent chemotherapy only. The deceased patient from the combined therapy group had an incomplete resection.

This patient underwent OLT without adjuvant chemotherapy due to local recurrence after prior resection with neoadjuvant and adjuvant chemotherapy.

The deceased patient was initially diagnosed with hepatoblastoma and died 4 months posttransplant of postoperative complications.

All patients with embryonal sarcomas of the liver underwent surgical resection with negative margins, however the use of chemotherapy could not be ascertained. The overall survival of UESL patients in this study was 80% (4/5).

Postsurgical death. The patient also had chemotherapy alone and died 1.8 years after diagnosis.

One patient died of unrelated trauma.

One patient had no outcome reported.

John Wiley & Sons, Ltd.

As with other hepatic malignancies such as hepatoblastoma and hepatocellular carcinoma,[31](#pbc26272-bib-0031){ref-type="ref"}, [32](#pbc26272-bib-0032){ref-type="ref"} complete surgical resection is currently the mainstay of therapy for UESL.[12](#pbc26272-bib-0012){ref-type="ref"}, [15](#pbc26272-bib-0015){ref-type="ref"} A distinct survival difference is seen between patients who underwent resection and those who did not. A small subgroup of five patients underwent surgical resection alone. All these patients had negative resection margins. These patients also had a variable extent of hepatic resection that ranged from sectionectomy to trisectionectomy and OLT. This indicated that all these were not small localized tumors. In this small sample, children treated with surgical resection alone with negative margins and no nodal disease had 100% survival. Although no firm conclusions can be drawn from such a small sample size, these data still pose an interesting question that is worth examining should a larger dataset of these patients become available.

In cases in which hepatic lesions are deemed unresectable due to multifocality or proximity to vital structures, OLT is used to achieve local control.[22](#pbc26272-bib-0022){ref-type="ref"}, [33](#pbc26272-bib-0033){ref-type="ref"}, [34](#pbc26272-bib-0034){ref-type="ref"} Successful use of OLT in the treatment of UESL has been reported in a few small case reports and series,[21](#pbc26272-bib-0021){ref-type="ref"}, [35](#pbc26272-bib-0035){ref-type="ref"}, [36](#pbc26272-bib-0036){ref-type="ref"}, [37](#pbc26272-bib-0037){ref-type="ref"}, [38](#pbc26272-bib-0038){ref-type="ref"} and more recently in an analysis of the United Network for Organ Sharing database.[20](#pbc26272-bib-0020){ref-type="ref"} Among this dataset of 10 children who underwent OLT, 100% were alive at 5 years. The degree of success seen in this interesting, albeit limited amount of data suggest that OLT could be a valid method for achieving local control for UESL in children, and should be considered when confronted with unresectable lesions. However, this remains a small number of cases and further investigation is warranted.

The objective when treating most liver tumors is to achieve a resection with a negative margin. Surprisingly, positive margins were not found to be significant predictors of outcome in this dataset. Given the reportedly good response to chemotherapy,[28](#pbc26272-bib-0028){ref-type="ref"}, [39](#pbc26272-bib-0039){ref-type="ref"} adjuvant chemotherapy may be sufficient to control or eliminate residual disease after resection in UESL. Future examination of resection margin status using a larger patient population may provide a more definitive answer as to its significance.

Metastases have been reported to occur in 5--13% of children.[5](#pbc26272-bib-0005){ref-type="ref"}, [12](#pbc26272-bib-0012){ref-type="ref"} Successful treatment using surgical resection with chemotherapy has been reported.[12](#pbc26272-bib-0012){ref-type="ref"}, [21](#pbc26272-bib-0021){ref-type="ref"} In this dataset, metastases were present in 15% of patients for whom the records were available, and all these patients received chemotherapy as part of their treatment. These data show that patients who have metastatic disease may have a reasonable chance at long‐term survival with combined surgery and chemotherapy. However, this conclusion must be tempered by the few cases available and large proportion of missing data for this field.

Currently, there are no standard chemotherapy regimens designed specifically for UESL. Accordingly, regimens reported in the literature are varied, and protocols originally designed for the treatment of pediatric rhabdomyosarcoma or other soft tissue sarcomas are often employed.[5](#pbc26272-bib-0005){ref-type="ref"}, [14](#pbc26272-bib-0014){ref-type="ref"}, [21](#pbc26272-bib-0021){ref-type="ref"}, [24](#pbc26272-bib-0024){ref-type="ref"} The effectiveness of radiation therapy to prevent recurrence and improve survival in UESL is unknown. In a few cases, radiation therapy has been used in the postoperative setting to prevent recurrence in the tumor bed.[39](#pbc26272-bib-0039){ref-type="ref"}, [40](#pbc26272-bib-0040){ref-type="ref"} Also, Plant et al. reported that radiation therapy successfully treated lung and paraspinal metastases in two patients.[35](#pbc26272-bib-0035){ref-type="ref"} However, this analysis did not reveal a significant improvement in the OS of patients who received chemotherapy alone or radiation therapy. The lack of survival benefit with chemotherapy and radiation may be attributable to differences in patient populations. Patient receiving chemotherapy or radiation may have more advanced or aggressive disease. Unfortunately, information regarding disease extent is limited to tumor size and lymph node status.

The NCDB is a national database drawing on data centers from the entire United States. Accordingly, findings based on NCDB data may be more generalizable than findings based on data from a single institution. The limitations of this work include the retrospective nature of the data, the relatively limited sample size, and the lack of participation by many large independent children\'s hospitals in the NCDB. Also, staging of liver tumors according to Children\'s Oncology Group (COG) or pretreatment extent of disease (PRETEXT) staging was not available. No differentiation between the sequence of chemotherapy and surgical resection could be made, as these data were incomplete in many cases.

The data show that surgical resection is crucial and should be considered an integral part of treatment in children with UESL. Despite the absence of specific tumor staging information, outcomes in children is excellent with surgery or combined therapy. This offers valuable information for physicians in their discussions with patients and their families in regards to the proper treatment and prognosis for children with this rare liver tumor.
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